Tempest Therapeutics, Inc.

Equities

TPST

US87978U1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:57:00 2024-02-28 pm EST 5-day change 1st Jan Change
3.77 USD -4.31% Intraday chart for Tempest Therapeutics, Inc. +3.56% -14.09%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Caution -2- DJ
Tempest Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Top Premarket Decliners MT
Top Premarket Decliners MT
Health Care Down on Mixed Blessing of Obesity-Drug Promise -- Health Care Roundup DJ
HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating MT
Tempest Therapeutics' TPST-1120 Combination Therapy Delivers Improved Results in Updated Liver Cancer Study; Shares Jump MT
Tempest Therapeutics, Inc. Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study CI
Tempest Therapeutics, Inc. Announces Expanded Role for Sam Whiting as Chief Medical Officer and Head of Research and Development CI
Tempest Therapeutics, Inc. Announces Executive Changes CI
Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Tempest Therapeutics, Inc. to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers CI
Tempest Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Top Midday Gainers MT
Tempest Therapeutics, Inc. Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma CI
Tempest Therapeutics, Inc. Announces New Data from its TPST-1120 and TREX1 Programs at 2023 AACR Annual Meeting CI
Piper Sandler Adjusts Tempest Therapeutics' Price Target to $6 From $10, Keeps Overweight Rating MT
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tempest Therapeutics, Inc. to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting CI
Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. Enter into First Amendment to Loan and Security Agreement CI
Tempest Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Tempest Therapeutics, Inc. Announces Executive Changes CI
Ladenburg Thalmann Starts Tempest Therapeutics at Buy With $8 Price Target MT
Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Chart Tempest Therapeutics, Inc.
More charts
Tempest Therapeutics, Inc.(Tempest) is a clinical-stage oncology company. The Company is focused on developing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a range of tumors. The Company's two clinical programs include TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARa). TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, and is in Phase I monotherapy and combination trials in solid tumors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.94 USD
Average target price
20 USD
Spread / Average Target
+407.61%
Consensus
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW